(Non-SGX Report) IX Biopharma Ltd - Wafermine Out-Licensed for C.US$248m
Non- SGX Report: These equity research reports are not written by the SGX. SGX supports the distribution of the research reports by external...
87 Views
No more insights
𝛼SK or SearchENTITY
iX Biopharma (IXBIO SP)
iX Biopharma (IXBIO SP)
5
Analysis
Health Care • Singapore
iX Biopharma is a specialty pharmaceutical and nutraceutical company that develops and commercializes innovative therapies for pain and other health conditions, leveraging proprietary sublingual drug delivery technologies such as WaferiX and WaferlogiX. Key products in development include Wafermine (ketamine wafer) for pain and BnoX (buprenorphine). The company was founded in Singapore in 2008.
morex